Meeting
2019 ASCO Annual Meeting
A first-in-human, multicenter, open label, phase I study in patients with advanced and/or refractory solid malignancies to evaluate the safety of intravenously administered ATOR-1015.
Authors
Jeffrey Yachnin
Karolinska Institutet, Stockholm, Sweden
Jeffrey Yachnin , Gustav J Ullenhag , Ana Carneiro , Dorte Nielsen , Kristoffer Staal Rohrberg , Anne Månsson Kvarnhammar , Anna Dahlman , Erika Bågeman , Camilla Wennersten , Charlotte Astrid Russell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Clinical Trial Registration Number
NCT03782467
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS2653)
DOI
10.1200/JCO.2019.37.15_suppl.TPS2653
Abstract #
TPS2653
Poster Bd #
292b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors.
First Author: Toshio Shimizu
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase 1 trial of navitoclax and sorafenib in patients with refractory solid tumors with a hepatocellular carcinoma expansion cohort.
First Author: Oluwadunni Eunice Emiloju
Poster
2023 ASCO Annual Meeting
A phase I study of nelmastobart (hSTC810), an anti-BTN1A1 antibody, in patients with advanced solid tumors.
First Author: Soohyeon Lee
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Safety and preliminary efficacy of MIL93 in patients with advanced solid tumors: The monotherapy part of a phase 1 trial.
First Author: Jing Huang